China Pharma Holdings, Inc. (CPHI) Stock Price & Analysis
China Pharma Holdings, Inc. (CPHI) rose 0.75% to USD 0.72 as of June 10, 2026 at 04:43 UTC, according to Nexqual real-time market data.
CPHI last closed at USD 0.71; the session ranged USD 0.71–0.83 on volume of 156,220 shares. Market capitalization is $28.99M, with a 52-week range of USD 0.38–2.05 (ASE). Source: Nexqual, June 10, 2026 at 04:43 UTC.
Key Statistics (as of June 10, 2026 at 04:43 UTC)
| Price | USD 0.72 |
|---|---|
| Change | ▲ 0.75% (up) |
| Previous Close | USD 0.71 |
| Open | USD 0.74 |
| Day Range | USD 0.71 – 0.83 |
| 52-Week Range | USD 0.38 – 2.05 |
| Volume | 156,220 shares |
| Market Cap | $28.99M |
| Exchange | ASE |
Technical Analysis (CPHI)
Nexqual's technical model rates CPHI "NEUTRAL" based on 2 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 04:43 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 46.02 (neutral) |
| vs SMA50 | Above (USD 0.69) |
| MACD | 0.02 (positive) |
Analyst Ratings (CPHI)
Wall Street analysts rate CPHI "None", per Nexqual as of June 10, 2026 at 04:43 UTC.
| Consensus Rating | None |
|---|
Earnings (CPHI)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2011-09-30 | USD 40 vs est 60 ▼ miss |
| 2011-03-31 | USD 50 vs est 57.5 ▼ miss |
| 2010-12-31 | USD 95 vs est 78.33 ▲ beat |
Source: Nexqual, June 10, 2026 at 04:43 UTC.
Financials & Fundamentals (CPHI)
| Total Revenue | $4.14M |
|---|---|
| Revenue Growth (YoY) | +8.10% |
| Gross Margin | -3.18% |
| Operating Margin | -97.86% |
| Profit Margin | -76.92% |
| ROE | -20.91% |
| Debt / Equity | 17.09 |
| Current Ratio | 0.32 |
| Total Cash | $345,112 |
| Total Debt | $3.89M |
| Free Cash Flow | $1.05M |
Source: Nexqual, June 10, 2026 at 04:43 UTC.
Financial Health Score (CPHI)
Nexqual rates China Pharma Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:43 UTC.
| Growth | Strong — Revenue +21% YoY (annual) |
|---|---|
| Profitability | Critical — Gross margin -3%, operating -98% |
| Balance Sheet | Solid — $345K cash vs $4M debt |
| Cash Flow | Mixed — FCF $1M, slim 1.4% margin |
| Efficiency | Critical — ROE -21%, ROA -8.4% |
Ownership (CPHI)
| Insider Ownership | +6.62% |
|---|---|
| Institutional Ownership | +0.06% |
| Shares Outstanding | 40.52M |
| Float | 37.84M |
| Short % of Float | +0.03% |
Source: Nexqual, June 10, 2026 at 04:43 UTC.
Leadership (CPHI)
China Pharma Holdings, Inc. is led by Zhilin Li (age 72), President, CEO, Chairman & Interim CFO, per Nexqual as of June 10, 2026 at 04:43 UTC.
| President, CEO, Chairman & Interim CFO | Zhilin Li (age 72) |
|---|
From China Pharma Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-04-01)
Key Strengths & Strategy (as disclosed to the SEC)
- China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
- The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
- In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks.
- It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SXTC | China SXT Pharmaceuticals, Inc. | USD 1.56 | ▲ 8.33% |
| CREG | Smart Powerr Corp. | USD 0.22 | ▼ 23.45% |
| ZNB | Zeta Network Group | USD 1.26 | ▼ 12.5% |
| BIMI | BIMI International Medical Inc. | USD 0 | ▲ 0% |
| CFOR | OpGen, Inc. | USD 2 | ▲ 300% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:43 UTC. This page is informational and not investment advice.